bettapharma, an investment project of china everbright limited, listed on the chinext board of shenzhen stock exchange
business related 08 nov 2016
download pdf
betta pharmaceuticals co., ltd. (“bettapharma”), an investment project of china everbright limited (“cel”, stock code: 165.hk)’s medical & healthcare fund, was listed on the chinext board of shenzhen stock exchange as the first listed innovative pharma company, with stock code: 300558.
bettapharma is a national-level high-tech pharmaceutical company founded by a team of phd returnees. bettapharma has established an integrated organization of research and development, manufacturing, sales and marketing with emphasis r&d of innovative drugs and proprietary intellectual property rights. ever since its establishment in 2003, it has fully committed to r&d and manufacturing of first class national innovative drugs with proprietary intellectual property rights directed at diseases with significant impacts on human health such as malignant tumors, diabetes, cardiovascular and cerebrovascular diseases and so forth. a first class national innovative drug called icotinib hydrochloride tablets (conmana) fully developed by bettapharma is the first innovative small molecule-targeted anti-cancer drug with independent intellectual property rights in china.
currently, cel’s medical & healthcare fund has invested in 12 leading companies in healthcare industry at home and abroad, including hanxiputai, amcare, xiuzheng pharmaceutical, ambrx and etc. and has successfully exited from yuwell with profitable return.
for more information of bettapharma, please visit:
bettapharma is a national-level high-tech pharmaceutical company founded by a team of phd returnees. bettapharma has established an integrated organization of research and development, manufacturing, sales and marketing with emphasis r&d of innovative drugs and proprietary intellectual property rights. ever since its establishment in 2003, it has fully committed to r&d and manufacturing of first class national innovative drugs with proprietary intellectual property rights directed at diseases with significant impacts on human health such as malignant tumors, diabetes, cardiovascular and cerebrovascular diseases and so forth. a first class national innovative drug called icotinib hydrochloride tablets (conmana) fully developed by bettapharma is the first innovative small molecule-targeted anti-cancer drug with independent intellectual property rights in china.
currently, cel’s medical & healthcare fund has invested in 12 leading companies in healthcare industry at home and abroad, including hanxiputai, amcare, xiuzheng pharmaceutical, ambrx and etc. and has successfully exited from yuwell with profitable return.
for more information of bettapharma, please visit:
